Hamlet BioPharma AB (publ) (HAMLET-B.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 6.08 (+1.67%) as of
Key statistics
- Market cap
- 1.16B
- EPS (TTM)
- -0.30
- Dividend yield
- 0.00%
- 52-week range
- 4.00 – 8.96
- Beta
- 0.25
- Revenue (TTM)
- 54.65k
- Profit margin
- 0.00%
- Volume
- 86.91k
About Hamlet BioPharma AB (publ)
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company's products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer. Hamlet BioPharma AB (publ) was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023. Hamlet BioPharma AB (publ) has a collaboration agreement with University of Iowa for development of Alpha1H treatment for patients with severe bladder cancer. The company was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) operates as a subsidiary of Linnane Pharma AB.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Lund, Sweden
- Employees
- 6
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.